destiny pharma limited

Live (In Receivership)MatureSmall

destiny pharma limited Company Information

Share DESTINY PHARMA LIMITED

Company Number

03167025

Directors

William Love

Debra Barker

View All

Shareholders

undisclosed

william guy love

View All

Group Structure

View All

Industry

Other research and experimental development on natural sciences and engineering

 

Registered Address

c/o cork gully llp, 40, villiers street, london, WC2N 6NJ

destiny pharma limited Estimated Valuation

£1m

Pomanda estimates the enterprise value of DESTINY PHARMA LIMITED at £1m based on a Turnover of £831.6k and 1.24x industry multiple (adjusted for size and gross margin).

destiny pharma limited Estimated Valuation

£0

Pomanda estimates the enterprise value of DESTINY PHARMA LIMITED at £0 based on an EBITDA of £-6.7m and a 5.66x industry multiple (adjusted for size and gross margin).

destiny pharma limited Estimated Valuation

£18.7m

Pomanda estimates the enterprise value of DESTINY PHARMA LIMITED at £18.7m based on Net Assets of £9.2m and 2.03x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Destiny Pharma Limited Overview

Destiny Pharma Limited is a live company located in london, WC2N 6NJ with a Companies House number of 03167025. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in March 1996, it's largest shareholder is undisclosed with a 26.8% stake. Destiny Pharma Limited is a mature, small sized company, Pomanda has estimated its turnover at £831.6k with unknown growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Destiny Pharma Limited Health Check

Pomanda's financial health check has awarded Destiny Pharma Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating3out of 5
positive_score

3 Strong

positive_score

1 Regular

positive_score

5 Weak

size

Size

annual sales of £831.6k, make it smaller than the average company (£4.3m)

£831.6k - Destiny Pharma Limited

£4.3m - Industry AVG

growth

Growth

There is insufficient data available for this Key Performance Indicator!

- - Destiny Pharma Limited

- - Industry AVG

production

Production

with a gross margin of 46.9%, this company has a comparable cost of product (46.9%)

46.9% - Destiny Pharma Limited

46.9% - Industry AVG

profitability

Profitability

an operating margin of -810.1% make it less profitable than the average company (3.6%)

-810.1% - Destiny Pharma Limited

3.6% - Industry AVG

employees

Employees

with 22 employees, this is below the industry average (44)

22 - Destiny Pharma Limited

44 - Industry AVG

paystructure

Pay Structure

on an average salary of £165.3k, the company has a higher pay structure (£64.5k)

£165.3k - Destiny Pharma Limited

£64.5k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £37.8k, this is less efficient (£124k)

£37.8k - Destiny Pharma Limited

£124k - Industry AVG

debtordays

Debtor Days

There is insufficient data available for this Key Performance Indicator!

- - Destiny Pharma Limited

- - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 326 days, this is slower than average (44 days)

326 days - Destiny Pharma Limited

44 days - Industry AVG

stockdays

Stock Days

There is insufficient data available for this Key Performance Indicator!

- - Destiny Pharma Limited

- - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 431 weeks, this is more cash available to meet short term requirements (32 weeks)

431 weeks - Destiny Pharma Limited

32 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 7.7%, this is a lower level of debt than the average (44.4%)

7.7% - Destiny Pharma Limited

44.4% - Industry AVG

DESTINY PHARMA LIMITED financials

EXPORTms excel logo

Destiny Pharma Limited's latest turnover from December 2023 is £831.6 thousand and the company has net assets of £9.2 million. According to their latest financial statements, Destiny Pharma Limited has 22 employees and maintains cash reserves of £6.4 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
Turnover831,552
Other Income Or Grants
Cost Of Sales441,682
Gross Profit389,870
Admin Expenses7,125,8647,776,3446,286,9516,552,5125,584,7526,083,8573,221,8501,449,8031,204,6271,708,106712,1421,216,4901,521,0151,524,1221,897,369
Operating Profit-6,735,994-7,776,344-6,286,951-6,552,512-5,584,752-6,083,857-3,221,850-1,449,803-1,204,627-1,708,106-712,142-1,216,490-1,521,015-1,524,122-1,897,369
Interest Payable1
Interest Receivable289,75664,80015,52071,61163,47875,99910,4593977,66210,5054,80017,16440,74554,578159,035
Pre-Tax Profit-6,446,238-7,711,544-6,271,431-6,480,901-5,521,274-6,007,858-3,211,391-1,449,406-1,196,965-1,697,601-707,342-1,199,326-1,480,270-1,469,545-1,738,334
Tax789,2021,207,975931,9511,069,824813,250841,144233,908191,578181,932303,27686,414164,168217,424208,136234,169
Profit After Tax-5,657,036-6,503,569-5,339,480-5,411,077-4,708,024-5,166,714-2,977,483-1,257,828-1,015,033-1,394,325-620,928-1,035,158-1,262,846-1,261,409-1,504,165
Dividends Paid
Retained Profit-5,657,036-6,503,569-5,339,480-5,411,077-4,708,024-5,166,714-2,977,483-1,257,828-1,015,033-1,394,325-620,928-1,035,158-1,262,846-1,261,409-1,504,165
Employee Costs3,636,7763,567,5982,939,0292,245,5572,025,0852,278,1181,721,201505,292482,236440,806445,796550,270638,847638,622630,695
Number Of Employees222321171615121811111
EBITDA*-6,729,798-7,764,016-6,274,433-6,535,631-5,566,312-6,074,194-3,219,773-1,448,464-1,203,849-1,707,302-711,276-1,215,287-1,518,735-1,521,030-1,895,344

* Earnings Before Interest, Tax, Depreciation and Amortisation

Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
Tangible Assets19,23524,62135,88218,14132,92230,42122,3131,1612,5006026081,4742,6774,6716,591
Intangible Assets2,341,4692,261,4352,261,4352,261,435
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets2,360,7042,286,0562,297,3172,279,57632,92230,42122,3131,1612,5006026081,4742,6774,6716,591
Stock & work in progress
Trade Debtors18,947
Group Debtors
Misc Debtors1,214,1771,606,2661,339,8631,680,7661,044,900930,759277,126216,520424,901122,786202,037246,016243,782263,362
Cash6,382,6034,903,4614,645,5629,744,2177,479,6427,060,82111,724,0371,481,4921,118,5742,004,021537,266912,1211,951,7873,173,7384,632,454
misc current assets5,036,4065,059,641205,142
total current assets7,596,7806,509,7275,985,42511,424,9838,524,54213,027,98617,060,8041,698,0121,342,6632,428,922660,0521,114,1582,197,8033,417,5204,895,816
total assets9,957,4848,795,7838,282,74213,704,5598,557,46413,058,40717,083,1171,699,1731,345,1632,429,524660,6601,115,6322,200,4803,422,1914,902,407
Bank overdraft
Bank loan
Trade Creditors 395,428172,543218,156725,593513,508403,552151,58257,88139,156301,85674,44167,96188,32850,34895,469
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities372,888997,219555,280542,541284,631398,240245,89396,87655,187155,812231,51972,043101,36698,211271,897
total current liabilities768,3161,169,762773,4361,268,134798,139801,792397,475154,75794,343457,668305,960140,004189,694148,559367,366
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities768,3161,169,762773,4361,268,134798,139801,792397,475154,75794,343457,668305,960140,004189,694148,559367,366
net assets9,189,1687,626,0217,509,30612,436,4257,759,32512,256,61516,685,6421,544,4161,250,8201,971,856354,700975,6282,010,7863,273,6324,535,041
total shareholders funds9,189,1687,626,0217,509,30612,436,4257,759,32512,256,61516,685,6421,544,4161,250,8201,971,856354,700975,6282,010,7863,273,6324,535,041
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
Operating Activities
Operating Profit-6,735,994-7,776,344-6,286,951-6,552,512-5,584,752-6,083,857-3,221,850-1,449,803-1,204,627-1,708,106-712,142-1,216,490-1,521,015-1,524,122-1,897,369
Depreciation6,19612,32812,51816,88118,4409,6632,0771,3397788048661,2032,2803,0922,025
Amortisation
Tax789,2021,207,975931,9511,069,824813,250841,144233,908191,578181,932303,27686,414164,168217,424208,136234,169
Stock
Debtors-392,089266,403-340,903635,866114,141653,63360,606197,573-405,954302,115-79,251-43,9792,234-19,580263,362
Creditors222,885-45,613-507,437212,085109,956251,97093,70118,725-262,700227,4156,480-20,36737,980-45,12195,469
Accruals and Deferred Income-624,331441,93912,739257,910-113,609152,347149,01741,689-100,625-75,707159,476-29,3233,155-173,686271,897
Deferred Taxes & Provisions
Cash flow from operations-5,949,953-6,426,118-5,496,277-5,631,678-4,870,856-5,482,366-2,803,753-1,394,045-979,288-1,554,433-379,655-1,056,830-1,262,410-1,512,121-1,557,171
Investing Activities
capital expenditure-80,844-1,067-30,259-2,263,535-20,941-17,771-23,229-2,676-798-286-1,172-8,616
Change in Investments
cash flow from investments-80,844-1,067-30,259-2,263,535-20,941-17,771-23,229-2,676-798-286-1,172-8,616
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue7,220,1836,620,284412,36110,088,177210,734737,68718,118,7091,551,424293,9973,011,4816,039,206
interest289,75664,80015,52071,61163,47875,99910,4593977,66210,5054,80017,16440,74554,577159,035
cash flow from financing7,509,9396,685,084427,88110,159,788274,212813,68618,129,1681,551,821301,6593,021,9864,80017,16440,74554,5776,198,241
cash and cash equivalents
cash1,479,142257,899-5,098,6552,264,575418,821-4,663,21610,242,545362,918-885,4471,466,755-374,855-1,039,666-1,221,951-1,458,7164,632,454
overdraft
change in cash1,479,142257,899-5,098,6552,264,575418,821-4,663,21610,242,545362,918-885,4471,466,755-374,855-1,039,666-1,221,951-1,458,7164,632,454

destiny pharma limited Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for destiny pharma limited. Get real-time insights into destiny pharma limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Destiny Pharma Limited Competitor Analysis

competitor_analysis_table_img

Perform a competitor analysis for destiny pharma limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in WC2N area or any other competitors across 12 key performance metrics.

destiny pharma limited Ownership

DESTINY PHARMA LIMITED group structure

Destiny Pharma Limited has 1 subsidiary company.

Ultimate parent company

DESTINY PHARMA LIMITED

03167025

1 subsidiary

DESTINY PHARMA LIMITED Shareholders

undisclosed 26.75%
william guy love 10.58%
rossetta capital vg p ltd 6.36%
anthony joseph eagle 5.21%
carole lesley love 5.16%
charles wade 4.99%
jemima elizabeth wade 4.99%
rock nominees ltd 3.48%
nss trustees ltd & a. cohen & w. cohen 3.32%
wade furniture group ltd 2.87%

destiny pharma limited directors

Destiny Pharma Limited currently has 7 directors. The longest serving directors include Dr William Love (Jun 1996) and Mrs Debra Barker (Jan 2020).

officercountryagestartendrole
Dr William Love62 years Jun 1996- Director
Mrs Debra Barker62 years Jan 2020- Director
Mr Aled Williams55 years Jun 2022- Director
Mr Nigel BrooksbyEngland74 years Jun 2022- Director
Mr James Stearns45 years Jun 2022- Director
Sir Nigel Rudd78 years Jul 2023- Director
Mr Christopher Tovey59 years Sep 2023- Director

P&L

December 2023

turnover

831.6k

0%

operating profit

-6.7m

-13%

gross margin

46.9%

0%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

9.2m

+0.2%

total assets

10m

+0.13%

cash

6.4m

+0.3%

net assets

Total assets minus all liabilities

destiny pharma limited company details

company number

03167025

Type

Private limited with Share Capital

industry

72190 - Other research and experimental development on natural sciences and engineering

incorporation date

March 1996

age

29

incorporated

UK

ultimate parent company

None

accounts

Full Accounts

last accounts submitted

December 2023

previous names

destiny pharma plc (September 2024)

destiny pharma holdings limited (August 2017)

See more

accountant

-

auditor

CROWE UK LLP

address

c/o cork gully llp, 40, villiers street, london, WC2N 6NJ

Bank

NATIONAL WESTMINSTER BANK PLC

Legal Advisor

OSBORNE CLARKE LLP COVINGTON & BURLING LLP

destiny pharma limited Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 2 charges/mortgages relating to destiny pharma limited. Currently there are 0 open charges and 2 have been satisfied in the past.

destiny pharma limited Capital Raised & Share Issues BETA

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for DESTINY PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.

destiny pharma limited Companies House Filings - See Documents

datedescriptionview/download